Researchers report that a “liquid biopsy” blood test can detect signs of cancer returning months before doctors identify relapse on standard scans. The approach looks for tiny fragments of circulating tumour DNA (ctDNA) in a patient’s blood and checks for specific genetic changes associated with cancer.
The outlets describe the test as identifying ctDNA and using those genetic markers to flag recurrence earlier than imaging-based follow-up. The reporting emphasizes the potential for earlier detection, which could allow clinicians to monitor patients more closely or adjust treatment sooner, depending on the results. Both sources frame the work as a step toward improving how relapse is detected in routine clinical care.
While the articles share the same core description of how the blood test works, they provide limited additional details such as study size, cancer types, and how much earlier detection occurs versus scans. The differing coverage is therefore mainly in phrasing rather than in the underlying reported method and goal.
